Mika Lehto1, Jussi Niiranen1, Pasi Korhonen2, Juha Mehtälä2, Houssem Khanfir2, Fabian Hoti2, Riitta Lassila3, Pekka Raatikainen1,4. 1. Department of Cardiology, Heart and Lung Center, University of Helsinki, Helsinki University Hospital, Helsinki, Finland. 2. EPID Research Oy, Espoo, Finland. 3. Department of Hematology, Comprehensive Cancer Center, University of Helsinki, Helsinki University Hospital, Helsinki, Finland. 4. University of Eastern Finland, Jyväskylä, Finland.
Abstract
PURPOSE: The most important management strategy in atrial fibrillation (AF) patients is preventing stroke with oral anticoagulants. Warfarin is still used as a first-line anticoagulant, although non-vitamin K antagonist oral anticoagulants are currently recommended to manage AF. Using a large, unselected national sample of AF patients, we evaluated the relationships between quality of warfarin therapy and the risks of thromboembolism, bleeding complications, and mortality. METHODS: The nationwide FinWAF study included 54 568 AF patients taking warfarin. Time in the therapeutic range (TTR) was calculated on a continuous basis using the Rosendaal method and international normalized ratio values over the previous 60 days. Adjusted Cox proportional hazard models were prepared for different TTR levels and major clinical end points. RESULTS: The mean age of patients was 73.1 years (standard deviation 10.8), and 47% were female. The mean follow-up time was 3.2 ± 1.6 years (median 3.4). In the TTR groups of ≤40%, 60-70%, 70-80%, and >80%, the annual risk of stroke was 9.3%, 4.7%, 4.6%, and 3.1%; bleeding events 7.5%, 4.5%, 4.3%, and 2.6%; and overall mortality 20.9%, 8.5%, 6.4%, and 3.1%, respectively. All differences among the TTR groups were highly significant (p < 0.001). CONCLUSIONS: The quality of warfarin treatment was strongly associated with the risk of stroke and the prognosis of AF patients. Patient outcomes continued to improve with increasing TTR values up to a TTR ≥80%; therefore, the target for the TTR should exceed 80% instead of the traditional range of at least 60-70%.
PURPOSE: The most important management strategy in atrial fibrillation (AF) patients is preventing stroke with oral anticoagulants. Warfarin is still used as a first-line anticoagulant, although non-vitamin K antagonist oral anticoagulants are currently recommended to manage AF. Using a large, unselected national sample of AFpatients, we evaluated the relationships between quality of warfarin therapy and the risks of thromboembolism, bleeding complications, and mortality. METHODS: The nationwide FinWAF study included 54 568 AFpatients taking warfarin. Time in the therapeutic range (TTR) was calculated on a continuous basis using the Rosendaal method and international normalized ratio values over the previous 60 days. Adjusted Cox proportional hazard models were prepared for different TTR levels and major clinical end points. RESULTS: The mean age of patients was 73.1 years (standard deviation 10.8), and 47% were female. The mean follow-up time was 3.2 ± 1.6 years (median 3.4). In the TTR groups of ≤40%, 60-70%, 70-80%, and >80%, the annual risk of stroke was 9.3%, 4.7%, 4.6%, and 3.1%; bleeding events 7.5%, 4.5%, 4.3%, and 2.6%; and overall mortality 20.9%, 8.5%, 6.4%, and 3.1%, respectively. All differences among the TTR groups were highly significant (p < 0.001). CONCLUSIONS: The quality of warfarin treatment was strongly associated with the risk of stroke and the prognosis of AFpatients. Patient outcomes continued to improve with increasing TTR values up to a TTR ≥80%; therefore, the target for the TTR should exceed 80% instead of the traditional range of at least 60-70%.
Authors: Taru Hallinen; Erkki Soini; Christian Asseburg; Miika Linna; Pia Eloranta; Sari Sintonen; Mikko Kosunen Journal: Clinicoecon Outcomes Res Date: 2021-08-13
Authors: Aníbal García-Sempere; Isabel Hurtado; Daniel Bejarano-Quisoboni; Clara Rodríguez-Bernal; Yared Santa-Ana; Salvador Peiró; Gabriel Sanfélix-Gimeno Journal: PLoS One Date: 2019-02-12 Impact factor: 3.240
Authors: Aníbal García-Sempere; Isabel Hurtado; Daniel Bejarano; Yared Santa-Ana; Clara Rodríguez-Bernal; Salvador Peiró; Gabriel Sanfélix-Gimeno Journal: Med Care Date: 2020-04 Impact factor: 3.178
Authors: Anna-Leena Vuorinen; Mika Lehto; Mikko Niemi; Kari Harno; Juha Pajula; Mark van Gils; Jaakko Lähteenmäki Journal: Clin Epidemiol Date: 2021-03-08 Impact factor: 4.790
Authors: Mika Lehto; Olli Halminen; Pirjo Mustonen; Jukka Putaala; Miika Linna; Janne Kinnunen; Elis Kouki; Jussi Niiranen; Juha Hartikainen; Jari Haukka; Kari Eino Juhani Airaksinen Journal: Eur J Epidemiol Date: 2022-01-05 Impact factor: 8.082
Authors: Alexandros A Polymeris; Thomas R Meinel; Jan C Purrucker; David J Seiffge; Hannah Oehler; Kyra Hölscher; Annaelle Zietz; Jan F Scheitz; Christian H Nolte; Christoph Stretz; Shadi Yaghi; Svenja Stoll; Ruihao Wang; Karl Georg Häusler; Simon Hellwig; Markus G Klammer; Simon Litmeier; Christopher R Leon Guerrero; Iman Moeini-Naghani; Patrik Michel; Davide Strambo; Alexander Salerno; Giovanni Bianco; Carlo Cereda; Timo Uphaus; Klaus Gröschel; Mira Katan; Susanne Wegener; Nils Peters; Stefan T Engelter; Philippe A Lyrer; Leo H Bonati; Lorenz Grunder; Peter Arthur Ringleb; Urs Fischer; Bernd Kallmünzer Journal: J Neurol Neurosurg Psychiatry Date: 2022-04-08 Impact factor: 13.654
Authors: Jaakko Lähteenmäki; Anna-Leena Vuorinen; Juha Pajula; Kari Harno; Mika Lehto; Mikko Niemi; Mark Van Gils Journal: Scand J Public Health Date: 2021-04-12 Impact factor: 3.199